---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-045723"
form_type: "8-K"
ticker: "EQ"
cik: "0001746466"
company_name: "Equillium, Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T04:00:00.650659+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Equillium Reports Q4 and Full Year 2024 Financial Results and Provides Clinical Updates

## Summary
- Phase 3 EQUATOR study in aGVHD: primary endpoint not met, but statistically significant longer-term outcomes (CR at Day 99, duration of CR, failure-free survival).
- Full year 2024 revenue $41.1M, up from $36.1M in 2023; net loss $8.1M ($0.23/share) vs $13.3M ($0.38/share) in 2023.
- Cash and investments $22.6M as of Dec 31, 2024; expected to fund operations into Q3 2025.
- FDA meeting requested for Accelerated Approval of itolizumab in aGVHD; feedback expected May 2025.
- Positive Phase 2 data for itolizumab in ulcerative colitis: clinical remission rate 23.3% vs 10.0% placebo at 12 weeks.

## SEC filing metadata
- accession: 0000950170-25-045723
- form_type: 8-K
- ticker: EQ
- cik: 0001746466
- company_name: Equillium, Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746466/000095017025045723/0000950170-25-045723-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746466/000095017025045723/eq-20250327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-045723
- JSON: https://secwatch.observer/filing/0000950170-25-045723.json
- Plain text: https://secwatch.observer/filing/0000950170-25-045723.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.